With a strong foundation in CF therapies and an expanding pipeline in pain management and other areas, Vertex demonstrates solid financial health with a robust gross margin of 86.1% and revenue of ...

U.S.-based companies are dragging down the major stock market indexes. But getting caught up in short-term market movements ...

With a strong foundation in CF therapies and an expanding pipeline in pain management and other areas, Vertex demonstrates solid financial health with a robust gross margin of 86.1% and revenue of ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

With a strong foundation in CF therapies and an expanding pipeline in pain management and other areas, Vertex demonstrates solid financial health with a robust gross margin of 86.1% and revenue of $11 ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Vertex was the first company to produce a medicine tackling the root cause of cystic fibrosis (CF) – mutations in a gene that codes for ion channels in cells that produce mucus, sweat ...

Boston, USA-based biotech Sionna Therapeutics has recently raised $191 million through its initial public offering (IPO), marking a step forward in its efforts to develop treatments for cystic ...

AbbVie, Danaher, Organovo, Thermo Fisher Scientific, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of ...

The news was greeted ecstatically by the CF community which had feared that a prolonged negotiation over pricing could delay the drug’s availability, as happened with Vertex’ two-drug therapy ...